The expression levels of both H19 and MALAT1 lncRNAs seem to be associated with patients' prognosis and clinical response to imatinib in advanced GIST harboring c-KIT mutations, suggesting a potential role for the clinical selection of the best candidate to first-line treatment. The gene discussed is MALAT1; the disease is gastrointestinal stromal tumor.